PMC9084234_01
Chest T.C. after Inotuzumab. A) Chest T.C. after the 1st dose of Inotuzumab. B) Chest CT after the 2nd dose of Inotuzumab.
mjhid-14-1-e2022043f1.jpg
PMC9084234_01_mjhid-14-1-e2022043f1.jpg
f1-mjhid-14-1-e2022043
However, on day 9, the clinical conditions worsened, with an acute respiratory syndrome requiring oxygen support; chest C.T. showed bilateral multilobar ground-glass opacities (Figure 1A). As already observed after the first dose, the respiratory syndrome worsened (Figure 1B) but again improved with oxygen and steroids support without non-invasive ventilation; fondaparinux was already ongoing for the pre-existing thrombosis.
Clinical and laboratory monitoring.
mjhid-14-1-e2022043f2.jpg
PMC9084234_01_mjhid-14-1-e2022043f2.jpg
f2-mjhid-14-1-e2022043
On day +49, we documented the presence of an antibody response to Sars-Cov2 (33.6 U/ml, cut-off >1U/ml), but the Sars-Cov2 nasopharyngeal swab was persistently positive (Figure 2); thus, convalescent plasma (CP, 200 ml/day continuous infusion for three days) was administered, without complications.